Tamoxifen Tales: Suggestions for Scientific Survival

by V. Craig Jordan

Overview

Tamoxifen Tales: Suggestions for Scientific Survival presents a case study describing the academic journey of teams behind major advances in medical sciences, highlighting lessons learned that are applicable to the next generation of scientists. This book provides a manual on the successful mentoring of young scientists, including stories describing how training experience shaped careers to become leaders in academia and the pharmaceutical industry. The book documents Professor V. Craig Jordan’s 50-year career in medical sciences that led to the discovery and development of Selective Estrogen Receptor Modulators (SERMs), which became the standard of women’s healthcare around the world.

Additionally, it illustrates the versatility of a scientist with a commitment to serving societies. This important resource will be a useful and interesting book for established medical scientists, research mentors and advanced students wanting to chart a successful and impactful research career.

• Highlights lessons learned from the journey behind discovery science that are applicable to the scientific journey of the next generation of scientists
• Provides a manual on the successful mentoring of young scientists to become leaders in academia and the pharmaceutical industry
• Examines cancer treatment based on a personal determination to challenge at the frontiers of the science and to relate to personal life experience
• Includes references for further research reading

Product Details

ISBN-13:	9780323859721
Publisher:	Elsevier Science
Publication date:	01/12/2022
Sold by:	Barnes & Noble
Format:	eBook
Pages:	312
File size:	131 MB
Note:	This product may take a few minutes to download.

About the Author

V. Craig Jordan is Professor of Breast Medical Oncology, Professor of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX. Previously, he was Scientific Director and Vice Chairman of Oncology at the Lombardi Comprehensive Cancer Center of Georgetown University. Jordan was the first to discover the breast cancer prevention properties of tamoxifen and the scientific principles for adjuvant therapy with antihormones. More recently his work has branched out into the prevention of multiple diseases in women with the discovery of the drug group, selective estrogen receptor modulator (SERMs). Currently, he plans to develop a new Hormone Replacement Therapy (HRT) for post-menopausal women that prevents breast cancer and does not increase the risk of breast cancer. In 2019 he was appointed Companion of the Most Distinguished Order of St. Michael and St. George by Queen Elizabeth II for services to women’s health.

Table of Contents

1. Beginnings
2. The University of Leeds: Foundation of a Career
3. The Chance to be a PhD Student at The University of Leeds
4. Two Antiestrogenic Strategies to Treat Breast Cancer at the Worcester Foundation
5. A New Strategy: Long-Term Adjuvant Tamoxifen Treatment and Other Discoveries at the University of Leeds
6. Tamoxifen’s Patenting Problems in America, Which Created a “Cancer Treatment Company”
7. Two Opportunities in Different Continents
8. The Good, The Bad and the Ugly of Tamoxifen at Wisconsin
9. “Sliding Door” and Serendipity
10. South to Northwestern in Chicago
11. Forward to the Fox Chase Cancer Center in Philadelphia
12. Get out and Go to Georgetown, Washington, DC
13. Closing the Circle of Tamoxifen Tales?
14. “If I Wanted to Buy Your Brain, What Would That Cost?”: Rebirth at MD Anderson
15. Invest in the Young
16. Scientific Survival Suggestions
17. An Account of PhD Students over 50 years of Tamoxifen Teams
18. Case Studies: In Their Own Words

What People are Saying About This

From the Publisher

Presents the scientific story behind the discovery of tamoxifen, reflecting on the versatility of the scientist and his perseverance, resilience and hard work

Editorial Reviews

"…. The story is engaging, the accomplishments remarkable and highly impactful. Dr. Jordan has not only mentored his students and fellows, he has helped support their educational expenses on occasion and has endowed lectureships in former institutions important to his development.

Finally, I am disheartened by one of the early vignettes in this book: Craig recounts his own struggle with metastatic renal cell carcinoma. Four years and all the usual therapies with good but waning results. May the ongoing search for another effective approach bear fruit. V. Craig Jordan still has much to contribute!" —The Cancer Letter

From the Publisher